Aarti Drugs Limited Net Assets
Aarti Drugs Limited net assets. Based on the latest financial reports, Aarti Drugs Limited (AARTIDRUGS) has net assets worth Rs15.49 Billion INR (≈ $167.54 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs28.15 Billion ≈ $304.46 Million USD) and total liabilities (Rs12.66 Billion ≈ $136.92 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Aarti Drugs Limited equity growth rate to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs15.49 Billion |
| % of Total Assets | 55.03% |
| Annual Growth Rate | 14.63% |
| 5-Year Change | 49.5% |
| 10-Year Change | 277.2% |
| Growth Volatility | 7.98 |
Net Assets of Aarti Drugs Limited (2006–2026)
Net assets of Aarti Drugs Limited from 2006 to 2026. This chart illustrates how Aarti Drugs Limited's net assets have evolved over time, based on quarterly financial data. See Aarti Drugs Limited net asset quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Aarti Drugs Limited (2006–2026)
The table below shows the annual net assets of Aarti Drugs Limited from 2006 to 2026. For live market cap and overall valuation, see Aarti Drugs Limited market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2026-03-31 | Rs15.49 Billion ≈ $167.54 Million |
+13.14% |
| 2025-03-31 | Rs13.69 Billion ≈ $148.09 Million |
+6.82% |
| 2024-03-31 | Rs12.82 Billion ≈ $138.64 Million |
+7.49% |
| 2023-03-31 | Rs11.93 Billion ≈ $128.98 Million |
+15.09% |
| 2022-03-31 | Rs10.36 Billion ≈ $112.07 Million |
+13.45% |
| 2021-03-31 | Rs9.13 Billion ≈ $98.78 Million |
+39.99% |
| 2020-03-31 | Rs6.52 Billion ≈ $70.56 Million |
+20.06% |
| 2019-03-31 | Rs5.43 Billion ≈ $58.77 Million |
+19.33% |
| 2018-03-31 | Rs4.55 Billion ≈ $49.25 Million |
+10.89% |
| 2017-03-31 | Rs4.11 Billion ≈ $44.42 Million |
+14.92% |
| 2016-03-31 | Rs3.57 Billion ≈ $38.65 Million |
+15.98% |
| 2015-03-31 | Rs3.08 Billion ≈ $33.33 Million |
+22.82% |
| 2014-03-31 | Rs2.51 Billion ≈ $27.13 Million |
+20.85% |
| 2013-03-31 | Rs2.08 Billion ≈ $22.45 Million |
+17.64% |
| 2012-03-31 | Rs1.76 Billion ≈ $19.09 Million |
+8.16% |
| 2011-03-31 | Rs1.63 Billion ≈ $17.65 Million |
+11.41% |
| 2010-03-31 | Rs1.46 Billion ≈ $15.84 Million |
+18.63% |
| 2009-03-31 | Rs1.23 Billion ≈ $13.35 Million |
+10.68% |
| 2008-03-31 | Rs1.12 Billion ≈ $12.06 Million |
+11.40% |
| 2007-03-31 | Rs1.00 Billion ≈ $10.83 Million |
-0.85% |
| 2006-03-31 | Rs1.01 Billion ≈ $10.92 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Aarti Drugs Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1400007200000.0% over the analyzed period, indicating profitable operations and earnings retention.
Aarti Drugs Limited Net Assets Breakdown (March 2026)
Aarti Drugs Limited net assets breakdown by equity component as of March 2026.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Rs14.00 Billion | 90.39% |
| Common Stock | Rs912.70 Million | 5.89% |
| Other Comprehensive Income | Rs575.84 Million | 3.72% |
| Total Equity | Rs15.49 Billion | 100.00% |
Aarti Drugs Limited Competitors by Market Cap
The table below lists competitors of Aarti Drugs Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jee Technology Co. Ltd. A
SHG:688162
|
$460.43 Million |
|
CapitaLand Malaysia Mall Trust
KLSE:5180
|
$460.45 Million |
|
Hailir Pesticides and Chemicals Group Co Ltd
SHG:603639
|
$460.48 Million |
|
Hainan Shuangcheng Pharmaceut
SHE:002693
|
$460.58 Million |
|
SKS Technologies Group Ltd
AU:SKS
|
$460.21 Million |
|
Shanghai Kindly Entrp Dvlp Grp
SHG:603987
|
$460.20 Million |
|
Kedge Construction Co Ltd
TW:2546
|
$460.11 Million |
|
Brisa Bridgestone Sabanci Lastik Sanayi ve Ticaret AS
IS:BRISA
|
$459.92 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Aarti Drugs Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2025 to 2026, total equity changed from 13,690,000,000 to 15,488,600,000, a change of 1,798,600,000 (13.1%).
- Net income of 1,949,197,000 contributed positively to equity growth.
- Dividend payments of 181,700,000 reduced retained earnings.
- Other comprehensive income increased equity by 201,211,001.
- Other factors decreased equity by 170,108,001.
Equity Change Factors (2025 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs1.95 Billion | +12.58% |
| Dividends Paid | Rs181.70 Million | -1.17% |
| Other Comprehensive Income | Rs201.21 Million | +1.3% |
| Other Changes | Rs-170.11 Million | -1.1% |
| Total Change | Rs- | 13.14% |
Book Value vs Market Value Analysis
This analysis compares Aarti Drugs Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.75x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 63.50x to 2.75x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-03-31 | Rs7.34 | Rs466.30 | x |
| 2007-03-31 | Rs10.69 | Rs466.30 | x |
| 2008-03-31 | Rs11.91 | Rs466.30 | x |
| 2009-03-31 | Rs13.18 | Rs466.30 | x |
| 2010-03-31 | Rs14.97 | Rs466.30 | x |
| 2011-03-31 | Rs16.84 | Rs466.30 | x |
| 2012-03-31 | Rs18.22 | Rs466.30 | x |
| 2013-03-31 | Rs21.43 | Rs466.30 | x |
| 2014-03-31 | Rs25.90 | Rs466.30 | x |
| 2015-03-31 | Rs31.81 | Rs466.30 | x |
| 2016-03-31 | Rs36.90 | Rs466.30 | x |
| 2017-03-31 | Rs43.04 | Rs466.30 | x |
| 2018-03-31 | Rs48.28 | Rs466.30 | x |
| 2019-03-31 | Rs57.61 | Rs466.30 | x |
| 2020-03-31 | Rs70.01 | Rs466.30 | x |
| 2021-03-31 | Rs98.01 | Rs466.30 | x |
| 2022-03-31 | Rs111.92 | Rs466.30 | x |
| 2023-03-31 | Rs128.77 | Rs466.30 | x |
| 2024-03-31 | Rs139.40 | Rs466.30 | x |
| 2025-03-31 | Rs149.39 | Rs466.30 | x |
| 2026-03-31 | Rs169.73 | Rs466.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Aarti Drugs Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 12.58%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 7.60%
- • Asset Turnover: 0.91x
- • Equity Multiplier: 1.82x
- Recent ROE (12.58%) is below the historical average (17.63%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 15.24% | 5.29% | 0.69x | 4.18x | Rs46.11 Million |
| 2007 | 13.75% | 4.76% | 0.79x | 3.66x | Rs37.56 Million |
| 2008 | 12.32% | 4.40% | 0.75x | 3.74x | Rs25.84 Million |
| 2009 | 12.93% | 4.18% | 0.95x | 3.27x | Rs36.21 Million |
| 2010 | 19.94% | 5.90% | 1.14x | 2.96x | Rs140.72 Million |
| 2011 | 14.53% | 4.73% | 0.96x | 3.21x | Rs73.97 Million |
| 2012 | 12.24% | 3.28% | 1.08x | 3.47x | Rs39.56 Million |
| 2013 | 21.79% | 5.48% | 1.15x | 3.47x | Rs244.78 Million |
| 2014 | 24.60% | 6.36% | 1.14x | 3.39x | Rs366.22 Million |
| 2015 | 25.07% | 7.06% | 1.09x | 3.25x | Rs464.39 Million |
| 2016 | 19.23% | 6.06% | 1.03x | 3.08x | Rs329.85 Million |
| 2017 | 19.62% | 6.74% | 1.02x | 2.87x | Rs394.91 Million |
| 2018 | 18.07% | 6.62% | 0.90x | 3.05x | Rs367.64 Million |
| 2019 | 16.52% | 5.75% | 1.07x | 2.69x | Rs354.07 Million |
| 2020 | 21.67% | 7.83% | 1.15x | 2.42x | Rs761.52 Million |
| 2021 | 30.70% | 13.01% | 1.22x | 1.93x | Rs1.89 Billion |
| 2022 | 19.78% | 8.24% | 1.13x | 2.13x | Rs1.01 Billion |
| 2023 | 13.95% | 6.12% | 1.12x | 2.03x | Rs470.67 Million |
| 2024 | 13.38% | 6.78% | 1.04x | 1.90x | Rs432.63 Million |
| 2025 | 12.28% | 7.04% | 0.93x | 1.88x | Rs312.60 Million |
| 2026 | 12.58% | 7.60% | 0.91x | 1.82x | Rs400.34 Million |
Industry Comparison
This section compares Aarti Drugs Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $18,808,468,359
- Average return on equity (ROE) among peers: 13.85%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Aarti Drugs Limited (AARTIDRUGS) | Rs15.49 Billion | 15.24% | 0.82x | $460.26 Million |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $1.38 Billion | 2.91% | 0.72x | $32.43 Million |
| Aarti Pharmalabs Limited (AARTIPHARM) | $15.58 Billion | 12.42% | 0.44x | $901.84 Million |
| Abbott India Limited (ABBOTINDIA) | $20.09 Billion | 22.42% | 0.46x | $5.93 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $37.90 Billion | 24.28% | 0.32x | $4.49 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $30.64 Billion | 11.04% | 0.34x | $1.26 Billion |
| Alkem Laboratories Limited (ALKEM) | $12.05 Billion | 19.50% | 0.29x | $6.77 Billion |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $949.51 Million | 15.88% | 0.30x | $155.76 Million |
| Alembic Pharmaceuticals Limited (APLLTD) | $27.18 Billion | 21.50% | 0.76x | $1.71 Billion |
| Aurobindo Pharma Limited (AUROPHARMA) | $23.50 Billion | -5.26% | 1.65x | $10.54 Billion |
About Aarti Drugs Limited
Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enro… Read more